 |
Daily News for Neuros, Nurses & Savvy Patients! |
|
|||||
My Educational Video on MS and MS Trials
|
|
|
|
|
| 10,000+ News links & stories! We Accept No Advertising This site is run by Facebook Volunteers. Visit our Facebook Page at: facebook.com/StansAngels |
||||||||
| 400,000+ Facebook & MySpace Visitors! MS News Channel Visitors: |
||||||||
 |
||||||||
 |
||||||||
 |
||||||||
 |
||||||||
 |
||||||||
 |
||||||||
 |
||||||||
 |
||||||||
 |
||||||||
 |
||||||||
 |
||||||||
 |
||||||||
 |
||||||||
 |
||||||||
 |
||||||||
 |
||||||||
 |
||||||||
| HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS | ||||||||
 |
||||||||
| ||||||||
| ||||||||
 Click to view 1280 MS Walk photos! | ||||||||
|
||||||||
|
||||||||
|
||||||||
 |
||||||||
| Previious Posts | ||||||||
|
||||||||
| MS NEWS ARCHIVES: by week | ||||||||
| November 2006 | ||||||||
| December 2006 | ||||||||
| January 2007 | ||||||||
| February 2007 | ||||||||
| March 2007 | ||||||||
| April 2007 | ||||||||
| May 2007 | ||||||||
| June 2007 | ||||||||
| November 2007 | ||||||||
| December 2007 | ||||||||
| February 2008 | ||||||||
| April 2008 | ||||||||
| May 2008 | ||||||||
| July 2008 | ||||||||
| August 2008 | ||||||||
| September 2008 | ||||||||
| October 2008 | ||||||||
| November 2008 | ||||||||
| December 2008 | ||||||||
| January 2009 | ||||||||
| February 2009 | ||||||||
| March 2009 | ||||||||
| April 2009 | ||||||||
| May 2009 | ||||||||
| June 2009 | ||||||||
| July 2009 | ||||||||
| August 2009 | ||||||||
| October 2009 | ||||||||
| November 2009 | ||||||||
| December 2009 | ||||||||
| January 2010 | ||||||||
| February 2010 | ||||||||
| March 2010 | ||||||||
| April 2010 | ||||||||
| May 2010 | ||||||||
| June 2010 | ||||||||
| July 2010 | ||||||||
| August 2010 |
8/13/10
Oprah Co. Sued for Multiple Sclerosis Discrimination
(Posted By: Josi Creek)
A woman who worked for Oprah Winfrey's OWN network claims she was subjected to a hostile work environment because she suffers from Multiple Sclerosis.
Read more »
A woman who worked for Oprah Winfrey's OWN network claims she was subjected to a hostile work environment because she suffers from Multiple Sclerosis.
Read more »
Labels: discrimination
8/6/10
Clinical Trials Necessary to Approve a Copaxone Generic
(Posted By: Josi Creek)
Any generic of Teva’s blockbuster multiple sclerosis treatment Copaxone would need clinical trials to gain approval, the company says in response to speculation that the FDA might approve a generic Copaxone using the same criteria it applied to generic Lovenox. “In the case of Copaxone and other complex molecules, there are no acceptable … tests either in humans or animals that can be relied upon except for complete clinical tests, which reflect the clinical outcome in multiple sclerosis,” Teva CEO Shlomo Yanai said.
Any generic of Teva’s blockbuster multiple sclerosis treatment Copaxone would need clinical trials to gain approval, the company says in response to speculation that the FDA might approve a generic Copaxone using the same criteria it applied to generic Lovenox. “In the case of Copaxone and other complex molecules, there are no acceptable … tests either in humans or animals that can be relied upon except for complete clinical tests, which reflect the clinical outcome in multiple sclerosis,” Teva CEO Shlomo Yanai said.
Labels: Copaxone, Research, Studies
8/5/10
Investigators Recruiting Globally For Phase II Study Of Oral Multiple Sclerosis Pill
(Posted By: Josi Creek)
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd.
Read more »
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd.
Read more »
8/2/10
Novel multiple sclerosis theory (CCSVI) dealt a blow by studies
(Posted By: Josi Creek)
A novel theory about the cause of multiple sclerosis — one that quickly led to millions of dollars in research pledges and an increasingly popular, though unproved, treatment — took a hit Monday from two studies calling the premise into question.
Read more »
A novel theory about the cause of multiple sclerosis — one that quickly led to millions of dollars in research pledges and an increasingly popular, though unproved, treatment — took a hit Monday from two studies calling the premise into question.
Read more »
Labels: CCSVI, Research, Studies
Gene Variant May Increase Severity of Multiple Sclerosis
(Posted By: Josi Creek)
A new study shows a gene variant may increase the severity of multiple sclerosis (MS) symptoms. The research will be published in the August 3, 2010, issue ofNeurology®, the medical journal of the American Academy of Neurology.
Read more »
A new study shows a gene variant may increase the severity of multiple sclerosis (MS) symptoms. The research will be published in the August 3, 2010, issue ofNeurology®, the medical journal of the American Academy of Neurology.
Read more »
Labels: genetics, Research, Studies
8/1/10
FDA Approves First Human Trial of Embryonic Stem Cells
(Posted By: Josi Creek)
The U.S. Food and Drug Administration approved the world’s first human clinical trial of a therapy involving embryonic stem cells, the biotechnology company behind the planned trial announced Friday.
Read more »
The U.S. Food and Drug Administration approved the world’s first human clinical trial of a therapy involving embryonic stem cells, the biotechnology company behind the planned trial announced Friday.
Read more »
Labels: Research, Stem Cell, Studies
Multiple Sclerosis To Be Diagnosed Earlier – Study
(Posted By: Josi Creek)
UCI immunological study finds earlier way to diagnose multiple sclerosis (MS).
Assessing for the increasing presence of antibodies that blocks energy production in neurons, UCI immunologists discovered that it can be used also in diagnosing multiple sclerosis at an earlier stage of the disease than the usual diagnostic tools.
Read more » 7/23/10
Teriflunomide and Glatiramer Acetate Combination Safe and Effective Against Relapsing-remitting Multiple Sclerosis
(Posted By: Josi Creek)
The current long-term therapies used to treat multiple sclerosis (MS) are administered intramuscularly or subcutaneously, producing local adverse effects at the sites of injection. Hence, the development of an orally administered drug would offer greater convenience and be more acceptable to patients. Teriflunomide is one of five such orally administered disease-modifying agents (used against rheumatoid arthritis) currently under investigation. Now, a Phase II trial conducted by researchers at the Mount Sinai School of Medicine reports teriflunomide to be safe and effective when used in conjunction with glatiramer acetate for the treatment of relapsing-remitting multiple sclerosis (RRMS).
The current long-term therapies used to treat multiple sclerosis (MS) are administered intramuscularly or subcutaneously, producing local adverse effects at the sites of injection. Hence, the development of an orally administered drug would offer greater convenience and be more acceptable to patients. Teriflunomide is one of five such orally administered disease-modifying agents (used against rheumatoid arthritis) currently under investigation. Now, a Phase II trial conducted by researchers at the Mount Sinai School of Medicine reports teriflunomide to be safe and effective when used in conjunction with glatiramer acetate for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Labels: Glatiramer acetate, Research
CCSVI Trial Set for This Fall
(Posted By: Josi Creek)
With health officials clamouring for more scientific research before green-lighting the new liberation treatment for multiple sclerosis (MS), local supporter and cardiovascular-thoracic surgeon Sandy McDonald is stepping up to provide it.
Read more »
Read more »
Labels: CCSVI
7/19/10
Upward Mobility with REX
(Posted By: Josi Creek)
When Robert Irving was diagnosed with Multiple Sclerosis it was the catalyst for him and his childhood friend, Richard Little, to put turn their engineering skills to the task of developing an exoskeleton that was a practical standing and walking alternative to wheelchairs. The result is REX, an exoskeleton made of strong, lightweight materials that is designed to support and hold a person comfortably as they move.
When Robert Irving was diagnosed with Multiple Sclerosis it was the catalyst for him and his childhood friend, Richard Little, to put turn their engineering skills to the task of developing an exoskeleton that was a practical standing and walking alternative to wheelchairs. The result is REX, an exoskeleton made of strong, lightweight materials that is designed to support and hold a person comfortably as they move.
Read more »
Labels: Walking and Mobility
6/27/10
Meat, Sausage and other foods can heighten risks of Multiple Sclerosis
(Posted By: Josi Creek)
Opinion from examination of information from seven EU countries introduced today by German epidemiologist Dr. Klaus Lauer, at the 20th Meeting of the European Neurological Society (ENS) in Berlin, Germany, stated that the facts presented as of currently are not affirmed informal link, but is an expressive implication that a link possibly does exist and needs to be completely researched.
Read more »
Opinion from examination of information from seven EU countries introduced today by German epidemiologist Dr. Klaus Lauer, at the 20th Meeting of the European Neurological Society (ENS) in Berlin, Germany, stated that the facts presented as of currently are not affirmed informal link, but is an expressive implication that a link possibly does exist and needs to be completely researched.
Read more »
Labels: Research
6/23/10
Multiple Sclerosis treatment, daclizumab in final clinical trial stage
(Posted By: Josi Creek)
Abbott Laboratories and its Massachusetts biotech partner have launched a final-stage clinical trial of their experimental treatment for multiple sclerosis.
The first patient — out of 1,500 needed worldwide — was enrolled last month in the U.S. The drug, daclizumab, is being developed for monthly injection under the patient’s skin by North Chicago-based Abbott and Cambridge-based Biogen Idec.
Read more »
Abbott Laboratories and its Massachusetts biotech partner have launched a final-stage clinical trial of their experimental treatment for multiple sclerosis.
The first patient — out of 1,500 needed worldwide — was enrolled last month in the U.S. The drug, daclizumab, is being developed for monthly injection under the patient’s skin by North Chicago-based Abbott and Cambridge-based Biogen Idec.
Read more »
Labels: Daclizumab
6/22/10
NIH Denies Request For Federal Funding to Study New Stem Cell Lines
(Posted By: Josi Creek)
A private lab’s request for federal funds to study 47 new stem cell colonies has been denied by National Institutes of Health director Francis Collins. The rejection comes after an advisory committee recommended against the approval citing the request violated strict ethical guidelines. Many scientists had hoped for an approval that would give them the ability to study various mutations of diseases. Diseases that were proposed to be studied included Huntington’s disease, cystic fibrosis and multiple sclerosis. Scientists believe the studying of these stem cell lines could have led to treatments for many of these incurable and often times deadly conditions.
Read more »
Read more »
6/21/10
Multiple Sclerosis in a War Zone
(Posted By: Josi Creek)
Can multiple sclerosis attacks be minimized in a war zone?
*An earlier study has shown that the stress of the Second Lebanon War in Israel increased the frequency of attacks in multiple sclerosis (MS) patients. The present study reveals that a potential way to minimize MS exacerbation is by directly coping with the situation. *
Read more »Labels: Research, Studies, Symptoms
6/20/10
GW Pharmaceuticals Sativex Cannabis is Psychoactive Free
(Posted By: Josi Creek)
Even if you were to track down the location and break into the computer-controlled greenhouse, the cannabis plants you would find at GW Pharmaceuticals' top-secret farm would be unlikely to give you the high you were hoping for.
Read more »Labels: Medical Marijuana, sativex
Study: Quality of care in Multiple Sclerosis
6/19/10
Study: Sativex effective on spasticity in people with multiple scleros
Study: Alzheimer’s Drug Memantine Not Effective in treating Multiple Sclerosis Cognitive Impairment
Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis
Study: Strains of Epstein-Barr virus infecting multiple sclerosis patients
High-dose immunoablation with stem cell transplant in aggressive multiple sclerosis: a 10 year study
Study: Psychiatric Symptoms at the onset of Multiple Sclerosis
6/18/10
GW Pharmaceuticals cannabis-based drug Sativex approved
.jpg)
A ground-breaking cannabis-based drug for treating symptoms of multiple sclerosis has been approved in Britain, in a landmark decision for its creator GW Pharmaceuticals.
Read more »Labels: Medical Marijuana, sativex
Novartis' Gilenia Pill May Shake Up Global MS Market
(Posted By: Josi Creek)
Novartis AG's novel multiple sclerosis pill Gilenia holds the potential to shake up the $10 billion multiple sclerosis market and give the Swiss pharmaceuticals giant a cutting edge over rivals such as Irish drug maker Elan Corp. PLC , U.S.-based Biogen Idec Inc. and Germany's Merck KGaA.
Read more »
Novartis AG's novel multiple sclerosis pill Gilenia holds the potential to shake up the $10 billion multiple sclerosis market and give the Swiss pharmaceuticals giant a cutting edge over rivals such as Irish drug maker Elan Corp. PLC , U.S.-based Biogen Idec Inc. and Germany's Merck KGaA.
Read more »
Labels: Fingolimod, Gilenia
6/16/10
Biogen Reports 6 More Brain Infection Cases In Tysabri Users
(Posted By: Josi Creek)
Biogen Idec Inc. (BIIB) disclosed six more cases of a rare brain infection in multiple sclerosis patients on Tysabri, which it sells with Elan Corp. (ELN), bringing the total number of cases to 55 as of June 7.
Read more »
Biogen Idec Inc. (BIIB) disclosed six more cases of a rare brain infection in multiple sclerosis patients on Tysabri, which it sells with Elan Corp. (ELN), bringing the total number of cases to 55 as of June 7.
Read more »
Labels: Tysabri
Breakthrough Finding from Israel may Lead to Earlier Diagnosis Multiple Sclerosis
A breakthrough finding from Israel may lead to earlier diagnosis, more effective intervention, and perhaps even a cure for the autoimmune disease multiple sclerosis.
"Those who will develop MS will show a different blood signature from those who will not," Prof. Anat Achiron, director of the Multiple Sclerosis Center at Sheba Medical Center.
Read more »
Study Provides Evidence that Add-on Rituximab Reduces Gadolinium-enhancing Brain Lesions in Multiple Sclerosis.
(Posted By: Josi Creek)
This is a study that shows very promising results for Rituximab.
Zamboni Says Vein Procedure Should be Offered in Clinical Trial
People with multiple sclerosis should be able to have surgery on blocked neck veins as part of a clinical trial, says the Italian doctor who pioneered what has become known as the liberation therapy.
Read more »Labels: CCSVI, Clinical Trials
6/15/10
Biogen Idec Announces Enrollment of First Patient in Oral Therapy Combination Trial in Multiple Sclerosis
(Posted By: Josi Creek)
Biogen Idec today announced enrollment of the first patient in a multicenter Phase II clinical trial designed to evaluate its investigational oral therapy BG-12 (dimethyl fumarate) in combination with commonly used first-line treatments in patients with relapsing-remitting multiple sclerosis (RRMS). The trial, called EXPLORE, will evaluate the safety and tolerability of BG-12 when administered with beta interferons (IFNB) or glatiramer acetate (GA) to patients who continue to have evidence of disease activity despite receiving consistent monotherapy for at least a year ,
Read more »
Biogen Idec today announced enrollment of the first patient in a multicenter Phase II clinical trial designed to evaluate its investigational oral therapy BG-12 (dimethyl fumarate) in combination with commonly used first-line treatments in patients with relapsing-remitting multiple sclerosis (RRMS). The trial, called EXPLORE, will evaluate the safety and tolerability of BG-12 when administered with beta interferons (IFNB) or glatiramer acetate (GA) to patients who continue to have evidence of disease activity despite receiving consistent monotherapy for at least a year ,
Read more »
Genzyme's MS drug, Alemtuzumab gets FDA fast track
(Posted By: Josi Creek)
Genzyme's multiple sclerosis drug candidate, Alemtuzumab was granted fast track status by the Food and Drug Administration, the company said Monday.
Genzyme's multiple sclerosis drug candidate, Alemtuzumab was granted fast track status by the Food and Drug Administration, the company said Monday.
The FDA grants fast track status to drug candidates that are designed to treat serious diseases, and which may be superior to current therapies. Fast track status includes additional collaboration between Genzyme and the FDA, and will allow Genzyme to submit portions of its application for the drug alemtuzumab as they are completed, rather than when all clinical testing is complete.
It also means alemtuzumab could get approved more quickly. Drugs that receive fast track status are more likely to get a priority review, which is complete in six months instead of the usual 10 months.
Labels: Alemtuzumab
Study: Changes in B- and T-cells & Chemokine Levels With Rituximab Treatment in Multiple Sclerosis
(Posted By: Josi Creek)
"In subjects with multiple sclerosis, B cells are critical for T-cell trafficking into the central nervous system and may alter the process by influencing chemokine production within the central nervous system."
Labels: Research, Studies, Tysabri
Study: Mental Activity protects against disease-related cognitive impairment associated with multiple sclerosis.
Study: Stem Cell Transplant Fails to Halt Demyelination: Inflammation of Multiple Sclerosis
(Posted By: Josi Creek)
"Demyelinating and inflammatory activities of MS persisted after allo-HSCT (allogeneic hematopoietic stem cell transplantation) in all of the patients with MS. Active and chronic active MS lesions exhibited significantly higher numbers of CD3+ T cells and CD8+ cytotoxic T cells and significantly higher scores of CD68+ microglia/macrophages than did chronic inactive lesions or normal-appearing white matter. The normal-appearing brains of allo-HSCT recipients who did not have MS were found to have significantly higher numbers of CD3+ T cells and CD8+ cytotoxic T cells and higher scores of CD68+ microglia/macrophages compared with the controls; however, no demyelination was identified in these non-MS samples."
"Demyelinating and inflammatory activities of MS persisted after allo-HSCT (allogeneic hematopoietic stem cell transplantation) in all of the patients with MS. Active and chronic active MS lesions exhibited significantly higher numbers of CD3+ T cells and CD8+ cytotoxic T cells and significantly higher scores of CD68+ microglia/macrophages than did chronic inactive lesions or normal-appearing white matter. The normal-appearing brains of allo-HSCT recipients who did not have MS were found to have significantly higher numbers of CD3+ T cells and CD8+ cytotoxic T cells and higher scores of CD68+ microglia/macrophages compared with the controls; however, no demyelination was identified in these non-MS samples."
Labels: Research, Stem Cell, Studies
6/12/10
Elan dealt a blow as rival drug, Gilenia, approved
(Posted By: Josi Creek)
ELAN, the Athlone-based pharmaceuticals company, has been dealt a blow after a rival to one of its leading drugs was approved by US regulators. The share dealt 2.5pc lower in New York yesterday.
Read more »
ELAN, the Athlone-based pharmaceuticals company, has been dealt a blow after a rival to one of its leading drugs was approved by US regulators. The share dealt 2.5pc lower in New York yesterday.
Read more »
Labels: Fingolimod, Gilenia, Tysabri
Virus can make immune cells attack nerves in multiple sclerosis
(Posted By: Josi Creek)
In young adults afflicted with multiple sclerosis (MS), a virus infection can incite the body to attack its own nerve tissue by activating unusual, disease-fighting cells with receptors for both viral and nerve proteins.
Read more » 6/11/10
Natalizumab an Alternative for Those in Whom Other MS Treatments Have Failed
(Posted By: Josi Creek)
A new study suggests that patients with relapsing-remitting multiple sclerosis (RRMS) in whom previous treatment regimens have failed remain stable or show improvement when switched to treatment with natalizumab (Tysabri, Novartis).
Read more »
A new study suggests that patients with relapsing-remitting multiple sclerosis (RRMS) in whom previous treatment regimens have failed remain stable or show improvement when switched to treatment with natalizumab (Tysabri, Novartis).
Read more »
Labels: Natalizumab, Tysabri
Team to test theory of vein efficiency in Multiple Sclerosis patients, and how to detect it
(Posted By: Josi Creek)
B.C. doctors will be part of a $2.4-million, two-year research study to look at whether a controversial treatment for multiple sclerosis is legitimate.
Read more »
B.C. doctors will be part of a $2.4-million, two-year research study to look at whether a controversial treatment for multiple sclerosis is legitimate.
Read more »
Labels: CCSVI
FDA panel recommends approval of first oral drug for multiple sclerosis
(Posted By: Josi Creek)
A Food and Drug Administration advisory panel on Thursday unanimously recommended approval of the first drug for multiple sclerosis (MS) that can be taken orally. Existing drugs for the disease have to be given intravenously or by injection. The new drug, targeted initially at relapsing-remitting MS, is called fingolimod and its manufacturer, Novartis, plans to use the brand name Gilenia. The agency is not required to follow the recommendations of its advisory panels, but it generally does.
Read more »
A Food and Drug Administration advisory panel on Thursday unanimously recommended approval of the first drug for multiple sclerosis (MS) that can be taken orally. Existing drugs for the disease have to be given intravenously or by injection. The new drug, targeted initially at relapsing-remitting MS, is called fingolimod and its manufacturer, Novartis, plans to use the brand name Gilenia. The agency is not required to follow the recommendations of its advisory panels, but it generally does.
Read more »
Labels: Fingolimod, Gilenia
Exercise Helps Multiple Sclerosis Patients
(Posted By: Josi Creek)
Patients with multiple sclerosis (MS) are able to exercise longer when they take intermittent rest breaks, according to a new study presented here at the Consortium of Multiple Sclerosis Centers 24th Annual Conference and the Third Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis.
Read more »
Patients with multiple sclerosis (MS) are able to exercise longer when they take intermittent rest breaks, according to a new study presented here at the Consortium of Multiple Sclerosis Centers 24th Annual Conference and the Third Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis.
Read more »
Vitamin D Linked to Poor Learning Performance in Patients With MS
(Posted By: Josi Creek)
A new study shows that serum vitamin D deficiency is associated with poor learning performance among patients with multiple sclerosis (MS). The research was presented here at the Consortium of Multiple Sclerosis Centers 24th Annual Conference and the Third Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis.
Read more » Physical Therapy Improves Urinary Symptoms in Patients With Multiple Sclerosis
(Posted By: Josi Creek)
A physical therapy regimen improves both urinary incontinence and urinary retention in patients with multiple sclerosis (MS), according to a study presented here at the Consortium of Multiple Sclerosis Centers 24th Annual Conference and the Third Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis.
Read more »
A physical therapy regimen improves both urinary incontinence and urinary retention in patients with multiple sclerosis (MS), according to a study presented here at the Consortium of Multiple Sclerosis Centers 24th Annual Conference and the Third Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis.
Read more »
Labels: Research, Weak Bladder
Vitamin D Exposure in Childhood Linked to Age at Onset of MS
(Posted By: Josi Creek)
Levels of childhood sun exposure and the presence or absence of cod liver oil supplements predict age at onset of multiple sclerosis (MS), a new study suggests.
Read more »
Levels of childhood sun exposure and the presence or absence of cod liver oil supplements predict age at onset of multiple sclerosis (MS), a new study suggests.
Read more »
6/10/10
New Multiple Sclerosis Drug , Fingolimod, Expected to be Approved by FDA
(Posted By: Josi Creek)
The panel that recommends drug approvals to the FDA has unanimously agreed that the multiple sclerosis drug, fingolimod is safe and effective. The panel is comprised of 25 medical experts not employed by the FDA. The proposed drug is manufactured by the Swiss company Novartis and would be marketed under the name Gilenia. If approved, the drug is expected to bring in more than one billion dollar in annual sales for the company.
Read more »
Labels: Fingolimod
6/9/10
Vitamin D Linked to Poor Learning Performance in Patients With Multiple Sclerosis
(Posted By: Josi Creek)
A new study shows that serum vitamin D deficiency is associated with poor learning performance among patients with multiple sclerosis (MS). The research was presented here at the Consortium of Multiple Sclerosis Centers 24th Annual Conference and the Third Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis.
Read more »
A new study shows that serum vitamin D deficiency is associated with poor learning performance among patients with multiple sclerosis (MS). The research was presented here at the Consortium of Multiple Sclerosis Centers 24th Annual Conference and the Third Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis.
Read more »
New Adult Stem-Cell Treatments Advance
(Posted By: Josi Creek)
New reports indicate that real hope for ‘miracle’ treatments using adult stem cells is on the way for those suffering from diseases afflicting both the brain and the heart.
Read more »
New reports indicate that real hope for ‘miracle’ treatments using adult stem cells is on the way for those suffering from diseases afflicting both the brain and the heart.
Read more »
6/8/10
Novartis’ Multiple Sclerosis Pill, Gilenia, Faces FDA Review
(Posted By: Josi Creek)
Novartis AG’s drug Gilenia has risks that may outweigh its benefit in treating multiple sclerosis, according to U.S. regulators reviewing whether to approve the first pill to slow progression of the disease.
Read more »
Novartis AG’s drug Gilenia has risks that may outweigh its benefit in treating multiple sclerosis, according to U.S. regulators reviewing whether to approve the first pill to slow progression of the disease.
Read more »
Labels: Gilenia, Oral Disease Modifying Drugs
6/7/10
Postpartum Steroids Reduce Multiple Sclerosis Relapses
(Posted By: Josi Creek)
A single dose of methylprednisolone given to new mothers with multiple sclerosis immediately after delivery reduced the risk of relapse for up to three months, researchers found.
Read more »
A single dose of methylprednisolone given to new mothers with multiple sclerosis immediately after delivery reduced the risk of relapse for up to three months, researchers found.
Read more »
Biogen’s CEO Retires Tomorrow
(Posted By: Josi Creek)
Biogen Idec will officially be CEO-less starting tomorrow. James Mullen, Biogen’s chief executive, retires on June 8 after a decade on the job and the Cambridge, MA-based company hasn’t named his successor.
Read more »
Biogen Idec will officially be CEO-less starting tomorrow. James Mullen, Biogen’s chief executive, retires on June 8 after a decade on the job and the Cambridge, MA-based company hasn’t named his successor.
Read more »
Labels: Tysabri
Simple eye test measures damage from multiple sclerosis
(Posted By: Josi Creek)
A quick, painless eye measurement shows promise as a way to diagnose multiple sclerosis in its very early stages, and to track the effectiveness of treatments, researchers from UT Southwestern Medical Center have found in a multicenter study. "This technique has the potential to provide a powerful and reliable assessment strategy to measure structural changes in the central nervous system, both for diagnostic purposes and in clinical trials to monitor whether potential treatments can prevent deterioration or restore nerve function," said Dr. Elliot Frohman, professor of neurology and ophthalmology, director of the Multiple Sclerosis Clinical Center at UT Southwestern and co-senior author of the study, which appears in the June issue of Annals of Neurology.
Read more »
A quick, painless eye measurement shows promise as a way to diagnose multiple sclerosis in its very early stages, and to track the effectiveness of treatments, researchers from UT Southwestern Medical Center have found in a multicenter study. "This technique has the potential to provide a powerful and reliable assessment strategy to measure structural changes in the central nervous system, both for diagnostic purposes and in clinical trials to monitor whether potential treatments can prevent deterioration or restore nerve function," said Dr. Elliot Frohman, professor of neurology and ophthalmology, director of the Multiple Sclerosis Clinical Center at UT Southwestern and co-senior author of the study, which appears in the June issue of Annals of Neurology.
Read more »
Labels: Research, technology
Costa Rica clamps down on dodgy stem cell treatments
(Posted By: Josi Creek)
Costa Rica has put an end to stem cell tourism, saying there's no evidence that the treatments work or are even safe.
Using stem cells from bone marrow, umbilical cords and other sources, Costa Rican clinics have been claiming to offer cures for injuries and degenerative diseases.
Read more »
Using stem cells from bone marrow, umbilical cords and other sources, Costa Rican clinics have been claiming to offer cures for injuries and degenerative diseases.
Read more »
Labels: Stem Cell
Multiple sclerosis patients who took oral fingolimod showed better results than those treated with injected interferon beta-1A,
(Posted By: Josi Creek)
Multiple sclerosis patients who took the oral investigational agent fingolimod were better able to maintain activities of daily living over a year than those treated with injected interferon beta-1A, according to a study presented here.
Read more »
Multiple sclerosis patients who took the oral investigational agent fingolimod were better able to maintain activities of daily living over a year than those treated with injected interferon beta-1A, according to a study presented here.
Read more »
Labels: Fingolimod, Studies
6/6/10
Bayer launches iPhone app to help people manage their multiple sclerosis treatment
(Posted By: Josi Creek)
This application was unveiled as part of Bayer’s patient support program, BETAPLUS, and it provides patients with injection reminders, injection site rotation assistance and injection history for BETASERON. Moreover, through the Internet, myBETAapp also gives patients access to the BETAPLUS web page from where users can access links to educational tools and get peer support. Patients enrolled in the BETAPLUS program can dial directly to speak to BETA Nurses, who are specially trained in MS.
This application was unveiled as part of Bayer’s patient support program, BETAPLUS, and it provides patients with injection reminders, injection site rotation assistance and injection history for BETASERON. Moreover, through the Internet, myBETAapp also gives patients access to the BETAPLUS web page from where users can access links to educational tools and get peer support. Patients enrolled in the BETAPLUS program can dial directly to speak to BETA Nurses, who are specially trained in MS.
Labels: Betaseron, technology
6/5/10
Investigational Oral Disease Modifying Drug Showing Improved Outcomes For Multiple Sclerosis patients
(Posted By: Josi Creek)
Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
Read more »
Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
Read more »
Labels: Oral Disease Modifying Drugs, Research
6/4/10
Safety fears hang over pioneering Novartis Multiple Sclerosis pill
(Posted By: Josi Creek)
"In clinical trials Gilenia has been linked to a range of worrying side effects, including skin cancer, heart problems and infections."
Read more »
Labels: Oral Disease Modifying Drugs
New Formulation of Copaxone:Teva Announces Positive Study Results
(Posted By: Josi Creek)
Significantly less pain and fewer injection site reactions were reported by patients receiving the new lower volume injection
Read more »Labels: Copaxone, Research, Studies
6/2/10
Stem Cell Therapies for Multiple Sclerosis Now Possible
(Posted By: Josi Creek)
A team of investigators from the University of California in Irvine (UCI) Sue & Bill Gross Stem Cell Research Center have recently made important strides in the field of using stem cells as therapies for mitigating the effects of injuries on the central nervous systems. The investigators managed to discover the mechanisms employed by adult neural stem cells, as they navigate through the human brain to the site of injuries, in order to fix the damages. This is the final piece to a puzzle that, once completely solved, could allow researchers to create new, stem cell-based therapies for inflammatory diseases of the brain, such as, for instance, multiple sclerosis (MS).
Read more »
A team of investigators from the University of California in Irvine (UCI) Sue & Bill Gross Stem Cell Research Center have recently made important strides in the field of using stem cells as therapies for mitigating the effects of injuries on the central nervous systems. The investigators managed to discover the mechanisms employed by adult neural stem cells, as they navigate through the human brain to the site of injuries, in order to fix the damages. This is the final piece to a puzzle that, once completely solved, could allow researchers to create new, stem cell-based therapies for inflammatory diseases of the brain, such as, for instance, multiple sclerosis (MS).
Read more »
6/1/10
Study: Epstein-Barr virus antibodies in serum and cerebrospinal fluid from Multiple sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Amyotrophic Lateral Sclerosis.
Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis
(Posted By: Josi Creek)
Traditional magnetic resonance imaging (MRI) techniques have contributed to the management of multiple sclerosis (MS) but are limited in their ability to detect neuronal damage. Advanced MRI metrics provide assessment of microscopic neuronal changes; however, few studies have examined the effects of MS therapies on these measures.
Traditional magnetic resonance imaging (MRI) techniques have contributed to the management of multiple sclerosis (MS) but are limited in their ability to detect neuronal damage. Advanced MRI metrics provide assessment of microscopic neuronal changes; however, few studies have examined the effects of MS therapies on these measures.
Labels: Glatiramer acetate, Research, Studies
A Study On Imaging of Spinal Cord Lesions
(Posted By: Josi Creek)
Study: Changes in Multiple Sclerosis Brain as shown on MRI
5/29/10
VIDEO: Ampyra helps MS patients to walk again
5/28/10
German pharma makes progress in new drugs to treat multiple sclerosis
(Posted By: Josi Creek)
“Multiple sclerosis patients can look forward to significant improvements in the treatment of the disease,” said Cornelia Yzer, general manager of the VFA, the German research-based pharmaceutical industry association. Ms Yzer’s speech marked this week’s World Multiple Sclerosis Day.
Read more »
“Multiple sclerosis patients can look forward to significant improvements in the treatment of the disease,” said Cornelia Yzer, general manager of the VFA, the German research-based pharmaceutical industry association. Ms Yzer’s speech marked this week’s World Multiple Sclerosis Day.
Read more »
Labels: Medications, Research, Studies
5/27/10
Lifetime cost of multiple sclerosis: $1.2 million per patient
(Posted By: Josi Creek)
In honor of World MS Day, the Multiple Sclerosis International Federation has released a report on the economic impact of the disabling autoimmune disease. Based on data from 15 countries, the report shows the average lifetime cost of MS is $1.2 million per patient - and "loss of employment, or early retirement, is considered the single largest cost factor contributing to this financial cost."
Read more »
In honor of World MS Day, the Multiple Sclerosis International Federation has released a report on the economic impact of the disabling autoimmune disease. Based on data from 15 countries, the report shows the average lifetime cost of MS is $1.2 million per patient - and "loss of employment, or early retirement, is considered the single largest cost factor contributing to this financial cost."
Labels: MS Awareness
Biogen Idec Globally Commemorates Annual World MS Day
(Posted By: Josi Creek)
On May 26, Biogen Idec will join the global multiple sclerosis (MS) community to commemorate the second annual World MS Day. Biogen Idec is a leader in the fight against MS, bringing hope to the thousands of patients across the globe who benefit from the company's MS therapies and ongoing research programs.
World MS Day was established by the Multiple Sclerosis International Federation to raise awareness of MS, national MS societies and those living with and affected by MS, to unite, broaden and mobilize the community and to support MS-directed fundraising. This year's World MS Day focuses on raising awareness of employment issues amongst those who are living with MS.
Read more »Labels: Ampyra, Injectable Disease Modifying Drugs
A study On Fatigue in multiple sclerosis
Study: Deep brain stimulation very good outcome for most patients with dystonia and tremor
5/24/10
Low Prenatal Sunlight Exposure May Increase Multiple Sclerosis Risk
(Posted By: Josi Creek)
Low maternal exposure to sunlight during the first trimester of pregnancy may increase the risk of offspring later developing multiple sclerosis (MS), a new Australian study suggests.
Read more »
Low maternal exposure to sunlight during the first trimester of pregnancy may increase the risk of offspring later developing multiple sclerosis (MS), a new Australian study suggests.
Read more »
Biogen Idec and Abbott Announce Enrollment of First Patient in Study of Daclizumab for Relapsing-Remitting Multiple Sclerosis
(Posted By: Josi Creek)
Read more »
Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX(R)) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). The trial, called DECIDE, will investigate a subcutaneous formulation of daclizumab intended for monthly administration, which has the potential to provide a new immunomodulatory approach for treating MS. Under the terms of the collaboration agreement, Biogen Idec will make a $30 million milestone payment to Abbott. This payment is due upon enrollment of the first patient in the DECIDE trial.
Labels: Clinical Trials, Daclizumab, Studies
5/21/10
Cannabis-based Sativex Multiple Sclerosis treatment set for UK approval
(Posted By: Josi Creek)
Read more »
Sativex, a ground-breaking cannabis-based drug for treating symptoms of multiple sclerosis (MS), could be approved in the UK by the end of June, its creator said on Thursday.
Labels: Medical Marijuana, Medications
Roche And Biogen Idec To Discontinue Ocrelizumab Clinical Development for Patients With Rheumatoid Arthritis
5/20/10
15-year follow-up study on Intramuscular Interferon
5/19/10
A Study: Autoimmune Diseases prior to Multiple Sclerosis Diagnosis
Alzheimer's Drug Trial On Multiple Sclerosis Patients for Cognitive Impairment
A Study On The Probability of Divorce in Multiple Sclerosis Patients
5/18/10
Acorda Therapeutics (Amprya) Recognized by National Organization for Rare Disorders for Contribution to Treatment of Multiple Sclerosis
Acorda Therapeutics, Inc. today announced the National Organization for Rare Disorders (NORD) is recognizing the Company for its efforts to develop therapies for rare diseases. Earlier this year, Acorda received approval from the U.S. Food and Drug Administration (FDA) for AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, the first therapy to improve walking in people with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. The award will be presented tonight at the 2010 NORD Partners in Progress Gala in Washington, D.C.
Read more »
Read more »
Labels: Ampyra, Medications
New Clinical Trial Of Investigational Multiple Sclerosis Treatment
5/16/10
Researchers seeking 1,000 who have Multiple Sclerosis
(Posted By: Josi Creek)
Duke University's medical research study at the N.C. Research Campus will recruit 1,000 people with multiple sclerosis to better understand how the unpredictable neurological disease progresses.
Ultimately, researchers want to find a cure for MS, which afflicts 400,000 Americans.
Read more »
Duke University's medical research study at the N.C. Research Campus will recruit 1,000 people with multiple sclerosis to better understand how the unpredictable neurological disease progresses.
Ultimately, researchers want to find a cure for MS, which afflicts 400,000 Americans.
Read more »
5/14/10
A Study: Copaxone (glatiramer acetate) Does not show significant affect on on Multiple Sclerosis Progression: Not affective for progressive forms
FDA denies Teva bid to block generic Copaxone
(Posted By: Josi Creek)
The US Food and Drug Administration has once again rejected Teva Pharmaceutical Industries’ request to stop approval of any generic versions of the Israeli company’s multiple sclerosis blockbuster Copaxone.
Read more »
The US Food and Drug Administration has once again rejected Teva Pharmaceutical Industries’ request to stop approval of any generic versions of the Israeli company’s multiple sclerosis blockbuster Copaxone.
Read more »
Labels: Copaxone
5/13/10
A study: Case of Long survival and clinical stability in Deadly variant of multiple sclerosis
(Posted By: Josi Creek)
"Marburg's variant multiple sclerosis is an acute and aggressive atypical form of MS, leading frequently to death in few months. "
"Marburg's variant multiple sclerosis is an acute and aggressive atypical form of MS, leading frequently to death in few months. "
Labels: Injectable Disease Modifying Drugs, Research, Studies
5/12/10
FDA To Target Misleading Drug Ads
(Posted By: Josi Creek)
"Last month, FDA sent a warning letter to Biogen Idec, Inc., for downplaying the risks of progressive multifocal leukoencephalopathy (PML), a rare, but often fatal, brain infection that has been linked to the multiple sclerosis drug Tysabri. The statements were made in a series of webcasts used to promote the drug between late October and early November of 2009."
Federal drug regulators are hoping to recruit doctors in the hunt for misleading drug advertisements through a new initiative aimed at marketing materials that provide inaccurate or misleading information, or make statements that downplay or omit the negative side effects of drugs.
Read more »
"Last month, FDA sent a warning letter to Biogen Idec, Inc., for downplaying the risks of progressive multifocal leukoencephalopathy (PML), a rare, but often fatal, brain infection that has been linked to the multiple sclerosis drug Tysabri. The statements were made in a series of webcasts used to promote the drug between late October and early November of 2009."
Federal drug regulators are hoping to recruit doctors in the hunt for misleading drug advertisements through a new initiative aimed at marketing materials that provide inaccurate or misleading information, or make statements that downplay or omit the negative side effects of drugs.
Read more »
Repeat Rituxan ( Rituximab) Therapy Helps in Resistant Rhumatoid Arthritis
(Posted By: Josi Creek)
Most patients with resistant rheumatoid arthritis who failed to respond to an initial cycle of rituximab (Rituxan) showed clinical improvement following a second treatment cycle, a British study found.
I wonder how this will effect those with MS who are taking Rituxan. Perhaps the results of this study show promise for both Multiple Sclerosis and Rhumatoid Arthritis patients.
Read more »
Most patients with resistant rheumatoid arthritis who failed to respond to an initial cycle of rituximab (Rituxan) showed clinical improvement following a second treatment cycle, a British study found.
I wonder how this will effect those with MS who are taking Rituxan. Perhaps the results of this study show promise for both Multiple Sclerosis and Rhumatoid Arthritis patients.
5/11/10
Study to Examine Emotional side of Multiple Sclerosis Looking For Participants
(Posted By: Josi Creek)
How do people with multiple sclerosis emotionally adjust to living with the debilitating disease?
That's the focus of a study by Melissa Kehler, a University of Regina doctoral psychology student, who is looking for 400 adult Canadians with MS to complete a one-time questionnaire that is available either online or in paper format.
Read more »
How do people with multiple sclerosis emotionally adjust to living with the debilitating disease?
That's the focus of a study by Melissa Kehler, a University of Regina doctoral psychology student, who is looking for 400 adult Canadians with MS to complete a one-time questionnaire that is available either online or in paper format.
Read more »
Liberation Procedure (CCSVI) for Multiple Sclerosis lands Victoria BC surgeon in hot water
(Posted By: Josi Creek)
Read more »
The B.C. woman who had the experimental neck vein procedure defends the treatment
Read more »
A Study: Health Toll On the Multiple Sclerosis Caregivers; What can be Done
Zebrafish may hold the Key to Restoring Myelin
A Medical Publication: Genes may play a role in Multiple Sclerosis patients response to Interfrerons
A study: additional eye damage in multiple sclerosis patients with or without optic neuritis
BERLENA HAS PHOTOS & AN AMAZING STORY ABOUT HOW AMPYRA HELPED HER WALKING ON HER CRUISE!
CLICK HERE TO GO TO OUR FACEBOOK PAGE & READ COMMENTS & (((HUGS)) OUR Facebook FRIENDS LEFT FOR
!
AND CLICK HERE TO READ 1000'S OF OTHER STORIES ABOUT OUR 2,700 Facebook FRIENDS LIKE BERLINA'S BELOW:
Stan, This is a comment my son made after looking at one of our pictures taken on the cruise ......... "Where did you take this?!?"! LOL! Very nice! I always enjoy hangin out with you and Pops...Broham (Pops) is finally coming around!...As for you, I'm so glad that you continue to take things in stride and don't let things stop you!....Just like a true Spencer!...Luv ya both!
Read more »Labels: Ampyra, Medications
Tysabri (natalizumab) may interfere with central nervous system immune surveillance.
A study about the immune system of the central nervous system itself, and how it is negatively affected by Tysabri. Could this could lead to further explinations for the cause of the many cases of PML?
Labels: PML, Research, Studies, Tysabri
A Case of Hydrocephalus during Natalizumab (Tysabri) treatment.
(Posted By: Josi Creek)
The headline of this story links to a medical publication of a case involving a woman suffering from multiple sclerosis who experienced an acute tetra-ventricular hydrocephalus soon after the beginning of immunomodulating treatment with natalizumab (Tysabri).
The headline of this story links to a medical publication of a case involving a woman suffering from multiple sclerosis who experienced an acute tetra-ventricular hydrocephalus soon after the beginning of immunomodulating treatment with natalizumab (Tysabri).
Labels: Research, Studies, Tysabri
Celebrities lend their support to Multiple Sclerosis survivor and advocate Nancy Davis
(Posted By: Josi Creek)
Avril Lavigne, Tia Carrere and Tom Arnold are just several of the celebrities lending their support to Multiple Sclerosis (MS) survivor and advocate Nancy Davis for May’s MS Awareness Month.
Read more »
Avril Lavigne, Tia Carrere and Tom Arnold are just several of the celebrities lending their support to Multiple Sclerosis (MS) survivor and advocate Nancy Davis for May’s MS Awareness Month.
Read more »
Labels: Charity Events, Determination
5/10/10
1.9 Million Dollar grant to help researchers explore new ways to reverse myelin damage caused by multiple sclerosis
(Posted By: Josi Creek)
About 400,000 Americans and about 2.5 million people worldwide suffer from MS, according to the National Multiple Sclerosis Society. The drugs that are available now focus mainly on controlling the inflammatory nature of the diseases to limit the development of neuronal damage. They do not reverse the damage caused by the disease. This research could lead to a huge medical breakthrough in the treatment of multiple sclerosis as well as other neurological conditions.
Read more »Labels: Myelin Repair, Research, Studies